한글목차

이 보고서는 경제 및 세계 불확실성이 지속되는 가운데, 역동적인 체외진단(IVD) 시장에 대한 최신 인사이트를 제공합니다.

2024년, IVD 시장은 COVID-19 검사 수익 감소에도 불구하고 대부분의 부문에서 성장세를 이어갈 것이며, AI를 통한 혁신, 규제 변화, 세계 헬스케어 지출의 변화가 경쟁 환경을 형성하고 IVD 분야의 회복력을 강화할 것으로 보입니다.

업계가 주목하고 IVD의 미래에 중요한 역할을 할 것으로 예상되는 주요 성장 분야는 다음과 같습니다:

세계의 체외진단(IVD) 시장에 대해 조사했으며, 시장 촉진요인과 주요 시장 동향, IVD 혁신을 형성하는 신제품 개발, 경쟁 구도 인사이트와 주요 기업 동향, 새로운 성장 기회와 전략적 성장 분야 등의 정보를 정리하여 전해드립니다.

목차

제1장 세계의 IVD 시장 최신 정보 - 2025년 4월

• IVD 시장 수요와 성장
• COVID-19 진단 시장
• COVID-19의 시장 부문에 대한 영향

제2장 제품 동향과 신개발

• 액체 생검
• 질량 분석
• 면역측정
• 분자
• 맞춤형 의료
• POC
• 시퀀싱
• 항원/항체
• 분자

제3장 IVD 시장의 주요 기업 결과

• 엄선된 경쟁 리더 최신 정보
• 2024년 4분기, 2025년 1분기 M&A 활동
• Abbott Laboratories
• Becton Dickinson and Co
• bioMerieux SA
• Danaher Corporation
• Dexcom, Inc
• Exact Sciences
• QuidelOrtho Corporation
• Roche Diagnostic
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific

제4장 새로운 기회

영문목차

Kalorama Information's "In Vitro Diagnostic (IVD) Trends and Market Update, 2025" provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year-first in April 2025 and again in Q4 2025, following the release of Kalorama's annual 1,600-page study, "The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition"-this report serves both as a standalone resource and a companion to Kalorama's annual flagship IVD analysis.

In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.

Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:

This report delivers timely and actionable intelligence, covering:

• Market drivers and major industry trends
• New product developments shaping IVD innovation
• Competitive landscape insights and activities of key players
• Emerging opportunities and strategic growth areas

With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.

Table of Contents

Chapter 1: Worldwide IVD Market Update - April 2025

• IVD Market Demand and Growth
  • Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
  • Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 - Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
  • Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
  • Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]

Chapter 2: Product Trends and New Developments

• Liquid Biopsy
• Mass Spectrometry
• Immunoassay
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
  • Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 - Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
• Q4 2024, Q1 2025 M&A Activity
  • Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
• bioMerieux SA
  • Table 3-4: bioMerieux Corporate Summary
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
• Dexcom, Inc
  • Table 3-6: Dexcom Corporate Summary
• Exact Sciences
  • Table 3-7: Exact Sciences Corporate Summary
• QuidelOrtho Corporation
  • Table 3-8: QuidelOrtho Corporate Summary
• Roche Diagnostic
  • Table 3-9: Roche Diagnostic Corporate Summary
• Siemens Healthineers
  • Table 3-10: Siemens Healthineers Corporate Summary
• Sysmex Corporation
  • Table 3-11: Sysmex Corporate Summary
• Thermo Fisher Scientific
  • Table 3-12: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

• Staffing Shortages
• LDT Update
• IVDR Compliance Deadline Approaches
  • Table 4-1: IVDR New Risk-based Classification System
• Telemedicine